CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.1.1 Top investment pockets
3.1.2 Top winning strategies
3.2 Porters Five Forces analysis
3.2.1 Bargaining power of the suppliers
3.2.2 Bargaining power of buyers
3.2.3 Threat of new entrants
3.2.4 Intensity of rivalry
3.2.5 Threat of substitutes
3.3 Market dynamics
3.3.1 Drivers
3.3.1.1 increasing prevalence of cancer
3.3.1.2 initiatives implemented by the government and non-government associations for rise in health awareness
3.3.1.3 technological advancements in exosomes isolation and analytical procedures
3.3.1.4 Innovative and advanced Applications of exosomes
3.3.2 Restraints
3.3.2.1 Technical difficulties in the usage of exosomes
3.3.2.2 Stringent regulatory requirements for the approval and commercialization of Exosome diagnostic and therapeutic products
3.3.2.3 low awareness and lack of skilled professionals required for the isolation of exosomes
3.3.3 Opportunities
3.3.3.1 developing economies offer lucarative growth opportunities
CHAPTER 4 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION
4.1 Overview
4.2 Diagnostic application
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Therapeutic application
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
CHAPTER 5 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT
5.1 Overview
5.2 Instrument
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.3 Reagents
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 Software
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
CHAPTER 6 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Cancer Institutes
6.2.1 Market size and forecast
6.3 Hospitals
6.3.1 Market size and forecast
6.4 Diagnostic Centers
6.4.1 Market size and forecast
6.5 Others
6.5.1 Market size and forecast
CHAPTER 7 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY GEOGRAPHY, 2015-2022
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.2.4 U.S.: market size and forecast
7.2.5 Canada market size and forecast
7.2.6 Mexico: market size and forecast
7.3 Europe
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.3.4 Germany: market size and forecast
7.3.5 France: market size and forecast
7.3.6 U.K.: market size and forecast
7.3.7 Italy market size and forecast
7.3.8 Rest of Europe: market size and forecast
7.4 Asia-Pacific
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.4.4 Japan: market size and forecast
7.4.5 China market size and forecast
7.4.6 Rest of Asia-Pacific: market size and forecast
7.5 LAMEA
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1 Aethlon Medical, Inc.
8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Business performance
8.1.4 Key strategic moves & developments
8.2 Exosome Diagnostics, Inc.
8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 Key strategic moves & developments
8.3 NanoSomix, Inc.
8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Business performance
8.3.4 Key strategic moves & developments
8.4 Thermo Fisher Scientific, Inc.
8.4.1 Company overview
8.4.2 Operating business segments
8.4.3 Business performance
8.4.4 Key strategic moves & developments
8.5 Malvern Instruments Ltd
8.5.1 Company overview
8.5.2 Operating business segments
8.5.3 Business performance
8.5.4 Key strategic moves & developments
8.6 System Biosciences, Inc.
8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key strategic moves & developments
8.7 NX PHARMAGEN
8.7.1 Company overview
8.7.2 Operating business segments
8.7.3 Business performance
8.7.4 Key strategic moves & developments
8.8 Sistemic Ltd.
8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key strategic moves & developments
8.9 Capricor Therapeutics, Inc.
8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Business performance
8.9.4 Key strategic moves & developments
8.10 Exiqon A/S
8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Business performance
8.10.4 Key strategic moves & developments
*Other players in the value chain include (players not profiled in the report)
101BIO
AMS Biotechnology Limited
Therapeutic Solutions International, Inc.
ReNeuron Group plc
Immune Therapy Holdings AB
ExoCyte Therapeutics Pte Ltd
Cell Guidance Systems LLC
BioRegenerative Sciences, Inc.
Evomic Science LLC
Norgen Biotek Corp.
*Profiles of these players are not included. The same will be included on request